MDACC Study No:2010-0504 ( NCT No: NCT01197170)
Title:Hormone receptor positive disease across solid tumor types: A Phase I Study of single-agent hormone blockade and combination approaches with targeted agents to provide synergy and overcome resistance
Principal Investigator:Jennifer J. Wheler
Treatment Agent:Anastrozole; Bevacizumab; Erlotinib; Everolimus; Fulvestrant; Sorafenib
Study Status:Open
Study Description:The goal of this clinical research study to find the highest tolerated dose of
anastrozole alone or in combination with either everolimus (Afinitor),
sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or
bevacizumab (Avastin) that can be given to patients with advanced cancer. The
safety of these drug combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Solid Tumors
Phase of Study:Phase I
Treatment Agents:Anastrozole
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jennifer J. Wheler
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults